Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05685173
Title A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Participants With Aggressive B-cell Non-Hodgkin Lymphomas (ATHENA-1)
Acronym ATHENA-1
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Regeneron Pharmaceuticals
Age Groups: adult | senior
Covered Countries USA | NLD | GBR | FRA | ESP

No variant requirements are available.